Patient access to pharmaceuticals: An international comparison

European Journal of Health Economics

Volumn 8, Issue 3, 2007, Pages 253-266

  Cohen, Joshua ^a,b   Faden, Laura ^a   Predaris, Susan ^a   Young, Brian ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG APPROVAL; DRUG INDUSTRY; FINANCIAL MANAGEMENT; FRANCE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; NETHERLANDS; PATIENT CARE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REIMBURSEMENT; UNITED KINGDOM; UNITED STATES;

COST SHARING; DRUG APPROVAL; FORMULARIES; FRANCE; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; INTERNATIONALITY; NETHERLANDS; PATIENT PARTICIPATION; PHARMACOPOEIAS AS TOPIC; PRESCRIPTIONS, DRUG; TIME FACTORS; UNITED STATES;

EID: 34547760765     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0028-z     Document Type: Article

References (56)

1. Association for the British pharmaceutical industry 2003 report: competitive task force-competitive and performance indicators 2003. See http://www.abpi.org.uk/publications, accessed June 1, 2006
2. Buchmueller, T., Couffinhal, A.: Private health insurance in France. OECD Health working paper No. 12. 2004. See http://www.oecd.org/els/health/ workingpapers, accessed April 5, 2006
3. Civitas. Are the NHS reforms working? NHS: is the extra money working? 2003. See http://www.civitas.org.uk/nhs/nhsmoney.php, accessed April 2, 2006
4. Cohen, J., Paquette, C., Cairns, C., Faden, L.: Comparing UK and US pharmacoeconomic assessments: case study of 38 NICE technology appraisals. Appl. Health Econ. Health Policy 5(3), 1-11 (2006)
5. Colombo, F., Tapay, N.: Private health insurance in OECD countries: the benefits and costs for individuals and health systems. OECD working paper 2005. See http://www.oecd.org/dataoecd/34/56/33698043.pdf, accessed March 10, 2006
6. Danzon, P.: Welfare effects of supplementary insurance: a comment. J. Health Econ. 21, 923-926 (2002)
7. Danzon, P., Ketcham, J.: Reference pricing of pharmaceuticals for medicare: evidence from Germany, the Netherlands, and New Zealand. NBER working paper series. See http://www.nber.org/papers/w1007, accessed March 7, 2006
8. Danzon, P., Wang, R., Wang, L.: The impact of price regulation on the launch delay of new drugs-evidence from 25 major markets in the 1990s. Health Econ. 14, 269-292 (2005)
9. Docteur, E., Oxley, H.: health-care systems: lessons from the reform experience. OECD working paper 2005. See http://www.oecd.org/dataoecd/5/53/ 22364122.pdf, accessed on march 10, 2006
10. Drug topics: top brand-name drugs by retail sales in 2005. See http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=104561, accessed on April 1, 2006
11. Fox, P.: Prescription drug benefits: cost management issues for Medicare. See http://www.cms.hhs.gov/apps/review/03_04winter/03_04winterpg7.pdf, accessed on April 5, 2006
12. Heffler, S., Smith, S., Keehan, S., Borger, C., Clemens, M., Truffer, C.: Trends: US health spending projections for 2004-2014. Health Affairs 2005 web exclusive. See http://content.healthaffairs. org/content/vol0/issue2005/images/ data/hlthaff.w5.74/DC1/Heffler05_E.5. gif, accessed on April 19, 2006
13. Hoadley, J., Hargrave, E., Cubanski, J., Neuman, T.: An in-depth examination of formularies and other features of Medicare drug plans. See http://www.kff.org/medicare/7489.cfm, accessed on May 29, 2006
14. Hoadley, J.: Cost containment strategies for prescription drugs - assessing the evidence in the literature, March 2005, http://www.kff.org, accessed on January 12, 2006
15. Hurwitz, B.: Legal and political considerations of clinical practice guidelines. BMJ 318, 661-664 (1999)
16. Jonsson, B., Wilking, N.: A pan-European comparison of patient access to cancer medications. See http://ki.se/content/1/c4/33/52/Cancer_Report.pdf, accessed on April 4, 2006
17. Lancry, P., et al.: Using health outcomes data to inform decision-making: healthcare payer perspective. Pharmacoeconomics 19(2), 39-47 (2001)
18. Le Pen, C.: Drug pricing and reimbursement in France: towards a new model? Pharmacoeconomics 10(Suppl. 3), 26-36 (1996)
19. Mossialos, E., Walley, T., Mrazek, M. (eds.) Regulating pharmaceuticals in Europe: an overview, striving for efficiency, equity, and quality. Open University Press, London (2004)
20. Neumann, P.: Why don't Americans use cost-effectiveness analysis. Am. J. Manag. Care 10(5), 308-312 (2004)
21. OECD Health Data 2005. See http://www.oecd.org, accessed on May 21, 2006
22. PDUFA, FDA and stakeholders public meeting. See http://www.fda.gov/ohrms/ dockets/05n0410/05n-0410-tr0001-vol2.pdf, accessed on March 24, 2006
23. Prescription drug coverage, spending, utilization, and prices. See http://www.aspe.hhs.gov, accessed on November 29, 2005
24. Pronk, M., Bonsel, G.: De budgetbeheersende functie van het geneesmiddelenvergoedingssysteem, 10 jaar GVS. Nederlands Tijdschrift voor de Geneeskunde. 146(37) (2002)
25. Rodwin, V., Sandier, S.: Health care under French national health insurance. See http://www.nyu.edu/projects/rodwin/french.html, accessed on January 11, 2006
26. Ryan, M.: Discrete choice experiments in health care. BMJ 328, 382 (2004)
27. See http://www.drugtopics.com/drugtopics/data/articlestandard/drugtopics/ 082006/309440/article.pdf, accessed on November 29, 2005
28. See http://www.cbg-meb.nl
29. See http://www.cbo.nl/home_html, accessed on June 1, 2006
30. See http://www.euro.who.int/Document/Obs/EuroObserver6_3.pdf, accessed on March 10, 2006
31. See http://www.irpp.org/events/archive/sep02/willison.pdf, accessed on March 25, 2006
32. See http://www.has-sante.fr, accessed on March 11, 2006
33. See http://afssaps-prd.afssaps.fr/html/has/sgt/htm/smr/indsmr.htm, accessed April on 19, 2006
34. See http://europa.eu.int/comm/enterprise/phabiocom/docs/tse/usa.pdf, accessed on March 25, 2006
35. See http://www.pbmi.com, accessed on January 31, 2006
36. See http://www.cbo.gov/ftpdocs/64xx/doc6481/06-16-PrescriptDrug.pdf, accessed on March 8, 2006
37. See http://www.amcp.org, accessed on March 10, 2006
38. See http://www.fda.gov, accessed on January 15, 2006
39. See http://www.mhra.gov.uk, accessed on February 23, 2006
40. See http://www.cbg-meb.nl, accessed on April 2, 2006
41. See http://www.afssaps.fr, accessed on March 3, 2006
42. See https://online.epocrates.com, accessed on May 31, 2006
43. See http://www.cvz.nl, accessed on March 1, 2006
44. See https://online.epocrates.com, accessed on May 29, 2006
45. See http://www.nice.org.uk, accessed on March 1, 2006
46. See http://www.has-sante.fr, accessed on March 23, 2006
47. See http://www.cms.hhs.gov/CapMarketUpdates/Downloads/hcimu120503.pdf, accessed on April 3, 2006
48. See http://www.pbmi.com, accessed on June 15, 2006
49. See http://www.fda.gov/oc/speeches/2003/eufeps1208.html, accessed on April 19, 2006
50. See http://www.who.int/intellectualproperty/studies/ Lanjouw_Price&LaunchFinal.pdf, accessed on April 5, 2006
51. Stolk, E., Brouwer, W., Busschbach, J.: Rationalizing rationing: economic and other considerations in the debate about funding of Viagra. Health Policy 59(1), 53-63 (2002)
52. Syrett, K.: A technocratic fix to the "legitimacy problem"? The Blair Government and Health Care Rationing in the United Kingdom. J. Health Polit. Policy Law 28, 715-746 (2003)
53. Ten leading nationwide 3-tier formularies, in terms of enrollment. See http://www.aishealth.com, accessed May on 23, 2006
54. Towse, A.: The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit? Health Aff. 22(3), 42-45 (2003)
55. Varkevisser, M., van der Geest, S.: "Price Competition Among Dutch Sickness Funds", Erasmus University Research Centre For Economic Policy Research Memorandum 0112, (2001). See http://www.ocfeb.nl, accessed on March 7, 2006
56. Whalen, J.: Britain stirs outcry by weighing benefits of drugs versus price. The Wall Street Journal, November 22, 2005